期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | THERAPIE LetPub Score 5.0
50 ratings
Rate
Reputation 6.0 Influence 3.7 Speed 7.0 | ||||||||||||||||
期刊簡稱 | THERAPIE | ||||||||||||||||
ISSN | 0040-5957 | ||||||||||||||||
E-ISSN | 1958-5578 | ||||||||||||||||
h-index | 33 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 27.30%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | http://www.therapielv.com/ | ||||||||||||||||
在線稿件提交 | |||||||||||||||||
開放訪問 | No | ||||||||||||||||
出版商 | Elsevier Masson SAS | ||||||||||||||||
主題領域 | 医学 | ||||||||||||||||
出版國/地區 | FRANCE | ||||||||||||||||
發行頻率 | 隔月刊行 | ||||||||||||||||
創刊年 | 1946 | ||||||||||||||||
每年文章數 | 73每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 44.50% | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q3
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0040-5957%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||
競爭力 * | 來自作者的數據: Easy | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[THERAPIE] 的評論 | 撰寫評論 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 17:17:37 評論於 Yes(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 15:19:40 評論於 The corresponding author of an SCI journal article does not necessarily have to be only one person, and there is no fixed standard for how many there can be. This is because different SCI journals have different policies regarding the number of corresponding authors. For SCI journals that only accept one corresponding author, if the paper has multiple corresponding authors, the first corresponding author will be automatically selected. For SCI journals that accept two corresponding authors, two corresponding authors can be listed. The same applies to other requirements, so the number of corresponding authors listed by the authors must comply with the regulations of the target SCI journal. The first author of an SCI paper is the person who has made the greatest contributions to the experiments and writing of the article, and is the person who is listed first in the authors section. However, in collaborations involving multiple authors, it is common to have multiple first authors. There is no clear rule regarding the number of co-first authors, as it depends greatly on the workload, length of the paper, requirements of the publishing journal, and recognition from institutions. Generally, having 2-4 first authors for an SCI paper is most common(0) 讚! | 维尔娜菲茨杰拉德 |
作者: Oswald Edie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 15:14:58 評論於 How many corresponding authors/first authors can a journal have?(0) 讚! | Oswald Edie |
作者: Oswald Edie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 13:31:21 評論於 Will all authors receive an email after the article is accepted?(0) 讚! | Oswald Edie |
作者: Alger Zimmerman 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-07-10 16:50:18 評論於 Review speed: 12.0 | Submission hit rate: 50.0 Experience sharing: with editor: 1 month | First review: 3 months | Revision: With editor again: 1 month | Second review: 3 months | Acceptance It took about 8 months to receive the acceptance letter. If you are in a hurry to publish, don't submit while in school(0) 讚! | Alger Zimmerman |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-14 18:34:09 評論於 Anyway, with this bearish market sentiment, there is unlikely to be any changes. As long as it doesn't drop, that's fortunate enough(0) 讚! | 凌霄高洁 |
作者: 努力啊大胜洋 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-06-13 18:39:43 評論於 Review speed: 1.0 | Submission success rate: 5.0 Experience sharing: Major revisions were still rejected(0) 讚! | 努力啊大胜洋 |
作者: 匿名 領域: 審稿時間: 0.0 month(s) 結果: 撰寫評論 |
2013-04-09 14:50:00 評論於 Journal Homepage URL: http://www.pharmacol-fr.org/(0) 讚! | 匿名 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us